Active substanceEthyl methylhydroxypyridine succinateEthyl methylhydroxypyridine succinate
Similar drugsTo uncover
  • Astrox
    solution w / m in / in 
    HOMEKSFARM LLC     Russia
  • Medomex®
    pills inwards 
       
  • Mexident®
    solution w / m in / in 
  • Mexidol®
    solution w / m in / in 
    FARMASOFT NPK, LLC     Russia
  • Mexidol®
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Mexidol® FORTE 250
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Mexicor®
    solution w / m in / in 
    EcoFarmInvest, LLC     Russia
  • Mexicor®
    capsules inwards 
    EcoFarmInvest, LLC     Russia
  • Mieleklek-Lekpharm
    solution w / m in / in 
    LEKFARM, SOOO     Republic of Belarus
  • Mexiprem ®
    solution w / m in / in 
    NIZHFARM, JSC     Russia
  • Mexiprem ®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Mexinin®
    solution w / m in / in 
    BRENDFARMA, LLC     Russia
  • Metostabil
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Metostabil
    pills inwards 
    ATOLL, LLC     Russia
  • MetucinWel
    solution w / m in / in 
    VELFARM, LLC     Republic of San Marino
  • Neurocardia
    solution w / m in / in 
  • Neurox®
    solution w / m in / in 
  • Proinin®
    solution w / m in / in 
  • Cerekard
    solution w / m in / in 
    EKOFARMPLUS, CJSC     Russia
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    Active substance: ethylmethyl hydroxypyridine succinate 50 g;

    Excipients: sodium metabisulphite 0.4 mg, water for injection up to 1 ml.

    Description:Colorless or slightly yellowish transparent liquid.
    Pharmacotherapeutic group:Antioxidant
    ATX: & nbsp

    N.07.X.X   Other drugs for the treatment of diseases of the nervous system

    Pharmacodynamics:

    Has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effect, increases the body's resistance to stress. The drug increases the resistance of the body to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral circulation, alcohol intoxication and antipsychotics (neuroleptics)).

    Meksidol® improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. Has hypolipidemic effect, reduces the level of total cholesterol and LDL.

    Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

    The mechanism of action of Mexidol® is due to its antihypoxic, antioxidant and membrane-protective action. It inhibits the processes of lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Meksidol® increases the content of dopamine in the brain. It causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of the mitochondria, stabilization of cell membranes. Mexidol® normalizes metabolic processes in ischemic myocardium, reduces the necrosis zone, restores and improves electrical activity and myocardial contractility,and also increases coronary blood flow in the ischemia zone, reduces the effects of reperfusion syndrome in acute coronary insufficiency. Increases antianginal activity nitropreparations. Mexidol® promotes the retention of retinal ganglion cells and optic nerve fibers in the course of progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves functional activity of the retina and optic nerve, increasing visual acuity.

    Pharmacokinetics:

    With the / m introduction is determined in the blood plasma for 4 hours after administration. Time to reach the maximum concentration TmOh - 0.45-0.5 hours. CmOh when a dose of 400-500 mg is administered, it is 3.5-4.0 μg / ml. Mexidol® quickly passes from the bloodstream into organs and tissues and quickly eliminates it from the body. The retention time of the preparation (MRT) is 0.7-1.3 hours. The drug is excreted mainly with urine, mainly in glucuronoconjugate form and in small amounts in unchanged form.

    Indications:

    - Acute disorders of cerebral circulation;

    - craniocerebral trauma, consequences of craniocerebral injuries;

    - encephalopathy;

    - syndrome of vegetative dystonia;

    - mild cognitive disorders of atherosclerotic origin;

    - anxiety disorders in neurotic and neurosis-like states;

    - acute myocardial infarction (from the first day) as part of complex therapy;

    - primary open-angle glaucoma of various stages, as part of complex therapy;

    - abstinence syndrome with alcoholism with predominance neurosis-like and vegetative-vascular disorders;

    - acute intoxication with antipsychotic drugs;

    - acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis) as part of complex therapy.

    Contraindications:

    Acute violations of liver and kidney function, increased individual sensitivity to the drug. Strictly controlled clinical trials of the safety of the use of Mexidol® in children, during pregnancy and breast-feeding were not carried out.

    Dosing and Administration:

    In / m or in / in (jet or drip). With the infusion method of administration, the drug should be diluted in a 0.9% solution of sodium chloride.

    Jet Meadol® is injected slowly for 5-7 minutes, drip - at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

    In acute disorders of cerebral circulation Mexidol® is used in the first 10-14 days - in / in the drip for 200-500 mg 2-4 times a day, then in / m 200-250 mg 2-3 times a day for 2 weeks.

    In case of craniocerebral trauma and consequences of craniocerebral injuries Meksidol® is used for 10-15 days in / in a drop of 200-500 mg 2-4 times a day.

    With discirculatory encephalopathy in the phase of decompensation Meksidol® should be administered intravenously or in droplet in a dose of 200-500 mg 1- 2 times a day for 14 days. Then in / m at 100-250 mg / day. for the next 2 weeks.

    For the course of prophylaxis of dyscirculatory encephalopathy the drug is given in / m in a dose of 200-250 mg twice a day for 10-14 days.

    With mild cognitive impairment in elderly patients and with anxiety disorders the drug is used in / m in a daily dose 100-300 mg / day for 14-30 days.

    With acute myocardial infarction as part of complex therapy Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy of myocardial infarction, including nitrates, beta-adrenoblockers, inhibitors angiotensin-converting enzyme (ACE), thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic drugs according to indications.

    In the first 5 days to achieve maximum effect, the drug is preferably administered intravenously, in the following 9 days Mexidol® can be administered intramuscularly. Intravenous administration of the drug is carried out by dropwise infusion, slowly (to avoid side effects) on a 0.9% solution of sodium chloride or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 min. If necessary, a slow jet injection of the drug, which lasts at least 5 minutes, is possible.

    Administration of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg / kg body weight per day, single dose - 2-3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

    With open-angle glaucoma of various stages in the complex therapy Meksidol® is administered intramuscularly at 100-300 mg / day, 1-3 times a day for 14 days.

    With abstinence alcohol syndrome Meksidol® is administered in a dose of 200-500 mg IV drip or in / m 2-3 times a day per day for 5-7 days.

    When acute intoxication with antipsychotic agents the drug is administered iv in a dose of 200-500 mg / day for 7-14 days.

    In acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis) the drug is prescribed on the first day in both the preoperative and postoperative period. The administered doses depend on the form and severity of the disease, the prevalence of the process, the variants of the clinical course. The drug should be phased out only after a stable positive clinical and laboratory effect.

    In acute edematous (interstitial) pancreatitis Mexidol® is prescribed 200-500 mg 3 times a day, iv drip (0.9% solution of sodium chloride) and in / m.

    Light severity of necrotic pancreatitis - 100-200 mg 3 times a day in / in the drip (in a 0.9% solution of sodium chloride) and in / m.

    Medium severity - 200 mg 3 times a day, in / in the drip (in a 0.9% solution of sodium chloride).

    Heavy current - in a pulsed dosage of 800 mg in the first day, with a two-fold mode of administration; further on 200-500 mg 2 times a day with gradual decrease in a daily dose.

    Extremely heavy current - in the initial dosage of 800 mg / day until the stable relief of pancreatogenic shock, to stabilize the state 300-500 mg 2 times a day in / drip (in a 0.9% solution of sodium chloride) with a gradual decrease in daily dosage.

    Side effects:Perhaps the appearance of nausea and dryness of the oral mucosa, drowsiness, allergic reactions.
    Overdose:Overdose may develop drowsiness.
    Interaction:

    Enhances the action of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa).

    Reduces the toxic effects of ethyl alcohol.

    Special instructions:

    In some cases, especially in predisposed patients with bronchial asthma with increased sensitivity to sulfites, it is possible to develop severe hypersensitivity reactions.

    Form release / dosage:Solution for intravenous and intramuscular injection, 50 mg / ml.
    Packaging:

    In ampoules of colorless or light-protective glass with a break point of 2 ml or 5 ml.

    5 ampoules per contour cell pack.

    For 1 or 2 contour mesh packages together with instructions for medical use in a pack of cardboard.

    By 20, 50, or 100 contour mesh packages, respectively, with 10, 25 or 50 instructions for medical use in boxes (for inpatient).

    Storage conditions:

    Store in a dry place protected from light out of the reach of children, at a temperature of no higher than 25 ° C.

    Shelf life:

    3 years.

    Do not use after the expiration date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002161 / 01
    Date of registration:14.03.2008 / 29.08.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:FARMASOFT NPK, LLC FARMASOFT NPK, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspFARMASOFT NPK LLC FARMASOFT NPK LLC Russia
    Information update date: & nbsp27.04.2018
    Illustrated instructions
      Instructions
      Up